Fuda Cancer Hospital
Fuda Cancer Hospital
Қытай, Гуаңджоу
| Қытай | Түркия | Австрия | |
| Halcyon | - | бастап $5,400 | - |
Сіз Bookimed қызметтері үшін төлемейсіз. мұрын-жұтқыншақ рагының емдеудің бағалары клиниканың баға тізіміне сәйкес келеді. Сіз жеткенде тікелей клиникада төлейсіз. Бөліктермен төлеу қолжетімді.
Bookimed Сіздің қауіпсіздігіңізді қамтамасыз етеді. Біз тек мұрын-жұтқыншақ рагының жүргізу үшін жоғары халықаралық стандарттарға сәйкес келетін клиникалармен ғана жұмыс істейміз. Олардың бүкіл әлем бойынша халықаралық науқастарға қызмет көрсету үшін қажетті лицензиялары бар.
Bookimed тегін көмек және қолдау ұсынады. Жеке медициналық координатор сапарға дейін, кезінде және кейін Сізбен байланыста. мұрын-жұтқыншақ рагының емдеу кезінде Сіз басқа елде жалғыз қалмайсыз.
Professor Shixin Liu, MD, PhD, is the Discipline Leader of the Oncology Center. He is the former President of Jilin Provincial Cancer Hospital and former Director of the Cancer Prevention and Treatment Research Institute. He is a second-level professor and doctoral supervisor. He has received the State Council Special Government Allowance, the 4th National Famous Doctor (Outstanding Contribution) award, and the Model of Medical Ethics honor.
He specializes in the comprehensive diagnosis and treatment of malignant tumors. His focus is precision radiotherapy for thoracic and abdominal cancers. He is skilled in IMRT, VMAT, and SBRT for lung, esophageal, breast, and rectal cancers.
His leadership roles include Vice Chair of CMA Radiation Oncology, CACA Radiotherapy, and CACA Particle Therapy. He serves on the CSCO Standing Committee and as Vice Chair of the CSCO Radiation Oncology Expert Committee. He is Vice Chair of CPAM Radiation Oncology and a Standing Committee member of CSMEA. He chairs the Jilin Medical Association Radiation Oncology branch. He is on the editorial boards of the Chinese Journal of Radiation Oncology and the Practical Journal of Cancer.
Patients choose China for nasopharyngeal cancer care due to the country's high case volume and clinical expertise. Chinese oncology centers manage nearly half of global cases annually. This experience allows surgeons and radiation oncologists to implement highly refined, standardized protocols. These specialized facilities often report 5-year survival rates exceeding 80%.
Bookimed Expert Insight: Data shows that centers in Guangzhou and Xiamen offer a significant experience advantage for head-and-neck cancers. Fuda Cancer Hospital has treated over 30,000 international patients using specialized minimally invasive tools. Dr. Liu Shi Xin in Xiamen is a State Council Special Government Allowance recipient. These credentials signal a level of expertise rarely found in regions where nasopharyngeal cancer is rare.
Patient Consensus: Patients emphasize that since this cancer is rare elsewhere, they seek Chinese teams for their routine expertise. Many note it is critical to find a center experienced in sparing salivary glands and cranial nerves during radiation.
China reports a 5-year survival rate for nasopharyngeal cancer (NPC) that meets or exceeds Western benchmarks in top-tier centers. Specialized facilities utilize high patient volumes and advanced radiotherapy to achieve these results. Survival outcomes globally depend significantly on early detection and modern radiation workflows.
Bookimed Expert Insight: Patient volume is a major quality signal for this specific cancer. Centers like Fuda Cancer Hospital have served over 30,000 international patients. This high throughput allows surgeons to refine complex techniques like NanoKnife and cryosurgery. Choosing a facility with massive yearly caseloads often leads to better survival outcomes than smaller clinics.
Patient Consensus: Patients note that specializing in head-and-neck oncology is vital for recovery. They often emphasize that centralized referral to high-volume centers helps catch the disease at earlier, more treatable stages.
Definitive Intensity-Modulated Radiotherapy (IMRT) is the gold standard for non-metastatic nasopharyngeal cancer in China. Specialists often combine it with systemic chemotherapy for advanced stages. This radiation-based approach yields 5-year survival rates exceeding 90% for stage I patients within Chinese oncology centers.
Bookimed Expert Insight: While most international protocols focus solely on radiation, Chinese centers like JCI-accredited Fuda Cancer Hospital emphasize specialized expertise in integrating minimally invasive therapies. Our data shows that high-volume providers often favor doctors with specific certifications, such as Dr. Liu Shi Xin, who holds multiple leadership roles in the Chinese Society of Clinical Oncology. This deep specialization in precision radiotherapy is crucial given that Chinese protocols are among the most aggressive globally due to high regional incidence.
Patient Consensus: Patients note that while the aggressive radiation-based approach is effective, prep for taste loss and severe mouth dryness is essential. Many recommend starting nutritional planning early to manage weight loss during the intensive treatment protocol.
Advanced treatments for nasopharyngeal cancer in China include PD-1 inhibitors like toripalimab and sintilimab. These immunotherapies are often paired with chemotherapy or precision radiation. JCI-accredited facilities offer next-generation ablation such as NanoKnife and cryosurgery. Chinese oncology centers maintain high 5-year survival rates through these multimodal protocols.
Bookimed Expert Insight: Data shows that Guangzhou hospitals often prioritize combining immunotherapy with microwave hyperthermia or vascular interventional therapy. Fuda Cancer Hospital has treated over 30,000 international patients using these combined minimally invasive methods. This multi-pronged approach is particularly effective for late-stage cases where traditional surgery is not viable. Doctors like Professor Liu Shi Xin also integrate precision radiotherapy to improve outcomes in thoracic and head-and-neck malignancies.
Patient Consensus: Patients emphasize that treatment plans are highly individualized based on EBV DNA markers and tumor response. Many note that advanced radiation delivery is just as critical as immunotherapy for long-term health.
Minimally invasive surgery is a viable option for recurrent nasopharyngeal cancer in China. It depends on the tumor location and prior radiation history. Specialists often use endoscopic transnasal approaches to remove small, localized recurrences. This avoids large incisions while preserving vital skull base structures.
Bookimed Expert Insight: Chinese oncology centers like Fuda Cancer Hospital demonstrate a unique focus on specialized non-drug therapies. They apply over 10 types of minimally invasive treatments, including vascular intervention and microwave hyperthermia. This variety allows doctors to treat advanced cases where standard chemotherapy may have already failed.
Patient Consensus: Patients note that prior radiation often makes tissues fragile. They emphasize that endoscopic skull base surgery is complex and requires highly experienced surgical teams.
Chinese oncology centers reduce radiation side effects by combining precision radiotherapy with Traditional Chinese Medicine to protect healthy tissue. High-volume facilities utilize Intensity-Modulated Radiotherapy and adaptive planning to sculpt beams around tumors. This approach minimizes damage to salivary glands and nearby vital organs.
Bookimed Expert Insight: Patient volume serves as a critical quality indicator in Chinese oncology. Fuda Cancer Hospital has served over 30,000 international patients. This high volume allows specialists like Dr. Liu Shi Xin at Xiamen Humanity Hospital to refine immobilization and toxicity tracking. Centers with such extensive experience often maintain more consistent protocols for managing acute side effects.
Patient Consensus: Patients note that while side effects like dry mouth and fatigue still occur, precision techniques make them more manageable. They emphasize that long-term preservation of speech and swallowing function is the primary goal of these advanced protocols.